Takeda to pull key hypoparathyroidism drug from the market after years of manufacturing woes
Takeda on Tuesday morning made an announcement that almost 3,000 people with the rare disease known as hypoparathyroidism were fearing.
Due to unresolved supply issues …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.